Moshe Inbar

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Martine Piccart, Marion Procter, Brian Leyland‐Jones et al. · New England Journal of Medicine · 2005 · 5.1K citations · Full text

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Christina Davies, Hongchao Pan, Jon Godwin et al. · The Lancet · 2012 · 2K citations · Full text

Breast Oncology, Long-term Effects, Medicine +7

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien, Nely Wigler, Moshe Inbar et al. · Annals of Oncology · 2004 · 1.7K citations · Full text

Liposomal Doxorubicin Hcl, Metastatic Breast Cancer, Oncology +8

High dose tumor necrosis factor-? and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation

Mordechai Gutman, Moshe Inbar, Dina Lev-Shlush et al. · Cancer · 1997 · 143 citations · Full text

Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment

Einat Shmueli, Nely Wigler, Moshe Inbar · European Journal of Cancer · 2003 · 125 citations

Neuro-oncology, Metastatic Breast Cancer, Oncology +5